MPN Research Foundation

MPN Research Foundation Patient-centric foundation that exists to fund research & improve outcomes for those living with MPNs Driving groundbreaking research. Improving lives.

Founded by patients for patients, MPN Research Foundation is a catalyst for research funding in pursuit of new treatments – and eventually a cure – for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms (MPNs). To date, we have funded more than $18 million in MPN research. Through a combination of MPN cancer research, advocacy and education, we bring together patients, researchers, and clinicians around the common goal of realizing new treatment options and ultimately, a cure for MPNs.

You and MPN Spotlight: Essential thrombocythemia (ET)!  Our new ET education module inside You and MPN: An Animated Pati...
04/10/2026

You and MPN Spotlight: Essential thrombocythemia (ET)!

Our new ET education module inside You and MPN: An Animated Patient’s Guide turns complex science into clear, research-backed information for patients and caregivers. Through animations, expert videos, patient storytelling, and visual tools, you can learn at your own pace — giving you a stronger foundation for understanding your disease and engaging in your care.

Explore the You and MPN: ET Module: https://f.mtr.cool/kxbzppehbo



In partnership with Mechanisms in Medicine.

You and MPN is made possible through independent educational grants from Disc Medicine, GSK, Incyte, Merck, PharmaEssentia, Sumitomo Pharma, and Takeda.

Every day, myeloproliferative neoplasm (MPN) patients make small decisions about their health: noticing new symptoms, ta...
04/07/2026

Every day, myeloproliferative neoplasm (MPN) patients make small decisions about their health: noticing new symptoms, taking medicines, managing fatigue, or deciding when to call their care team. These everyday actions are what the researchers call self‑care.

Recently, a team of researchers in Italy took a closer look at what motivates self‑care behaviors in people living with MPNs. Biagioli et al.’s goal was to understand why some individuals feel more prepared and confident to manage day‑to‑day challenges, and how care teams can better support this process (2026).

One of the most important insights from the study is this: feeling engaged in your care is not enough on its own. What truly drives better self‑care is feeling capable and confident in your ability to handle your illness.

Researchers call this confidence self‑efficacy — but in everyday terms, it simply means:

“I believe I can manage this. I know what to do, and I can do it.”

The Italian study found that when patients feel actively involved in their health decisions and receive clear, practical guidance from their care teams, they are much more likely to develop this sense of capability. And once patients feel capable, they are far more likely to follow through with the self-care that supports long‑term health. In fact, confidence was shown to be the key link between being engaged and actually performing strong self‑care behaviors.

“The findings highlighted in this article reinforce how essential education and engagement are for patients with MPNs,” said Sara Douglas, MSN, RN, OCN, Director of Patient Engagement at the MPN Research Foundation. This research echoes what many in the MPN community already know: “Nurses see firsthand that when patients are empowered with the right information, they are better equipped to care for themselves.”

Read more about it here: https://f.mtr.cool/pshmxfeglq

The March edition of Under the Microscope will hit your inboxes at 5PM CT today! This digest includes: 👉 Patient Profile...
03/31/2026

The March edition of Under the Microscope will hit your inboxes at 5PM CT today!

This digest includes:

👉 Patient Profile: Dr. Janeana White
👉 Clinical Update: New NCCN guidance on interferon in essential thrombocythemia (ET)
👉 Updated You and MPN modules Announcement
and more!

Join our community today to receive these stories and so much more with this link: https://f.mtr.cool/enzavtfyro

We’re excited to share THREE new “You and MPN” education modules, now covering essential thrombocythemia (ET), polycythe...
03/30/2026

We’re excited to share THREE new “You and MPN” education modules, now covering essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Explore the newly expanded You and MPN program — a multimedia learning experience built to make myeloproliferative neoplasm (MPN) science easier to follow and talk about with your care team.

Through animations, expert videos, and real patient stories, each module is designed to build confidence as you navigate your diagnosis.

Explore the program and share it with someone who might need it: https://f.mtr.cool/rqpssclxlr



In partnership with Mechanisms in Medicine.

You and MPN is made possible through independent educational grants from Disc Medicine, GSK, Incyte, Merck, PharmaEssentia, Sumitomo Pharma, and Takeda.

Our new MPN PROGRESSion Registry™ is open for enrollment. This patient-focused research initiative gathers comprehensive...
03/20/2026

Our new MPN PROGRESSion Registry™ is open for enrollment. This patient-focused research initiative gathers comprehensive myeloproliferative neoplasm (MPN) patient health data over 5-10 years. The goal is to help provide a better understanding of MPNs and why they can progress from one disease to another, or more rarely, to secondary acute myeloid leukemia (sAML).

This exciting milestone in the quest to slow, stop, or reverse that progression is made possible, in part, due to support from our industry partners.

🌟 A heartfelt thank you to , our newest MPN PROGRESSion Registry™ sponsor. Their backing helps make this groundbreaking research possible, and we are very appreciative! 🌟
___________________

If you're 18 or older, live in the U.S., and have ever been diagnosed with an MPN, joining is fast, easy, and secure.

👉 Enroll today: https://f.mtr.cool/iyxuroiwrc

We are proud to congratulate Dr. Ann Mullaly and colleagues on the publication of an important new study examining TP53-...
03/19/2026

We are proud to congratulate Dr. Ann Mullaly and colleagues on the publication of an important new study examining TP53-mutated myeloproliferative neoplasms (MPNs). This large, multi-institutional effort brings new clarity to a question many patients and clinicians face — why TP53 mutations lead to aggressive disease in some people, but not in others.

In this study by Rolles et al., the researchers analyzed data from more than 1,500 people with MPNs and developed a new way to better identify who may be at higher risk for disease progression. The researchers identified three key factors that matter in TP53-mutated MPNs: bone marrow scarring (fibrosis), the number of mutations to the TP53 gene, and how strongly the types of mutations to TP53 are affecting the cell’s activity. Together, these factors inform a new risk model that may help identify who needs closer monitoring and who may have a more stable disease course.

This kind of insight is essential for improving prognosis and personalized care in rare blood cancers.

MPN Research Foundation is honored to have supported this work by funding MPN data entry into the Hematologic Malignancy Data Repository at Dana-Farber Cancer Institute , which made this type of large, collaborative analysis possible. This study reflects what your support makes possible — advancing research improved prognosis, design smarter clinical trials, and move closer to more informed care for people living with MPNs.

We celebrate this milestone with the investigators and the entire research community working to improve outcomes for patients worldwide. Learn more here: https://f.mtr.cool/eoidznofkc

One week left to register! Don’t miss our next MPN Pathways: Empowered Voices in Research webinar, “Informed Consent,” h...
03/10/2026

One week left to register!

Don’t miss our next MPN Pathways: Empowered Voices in Research webinar, “Informed Consent,” happening Thursday, March 19 from 4-5pm CT.

Featuring Emily Largent, JD, PhD, RN, a leading bioethics scholar whose work focuses on human subjects research and the ethics of translating research to human care.

Learn how informed consent protects clinical trial participants, and how patient and caregiver perspectives help strengthen the process.

This webinar also counts toward completing the MPN Research Foundation Research Advocate Certification.

Can’t make it live? All registrants receive recording and post-session materials.

Register now: https://f.mtr.cool/osjkczusfq

This is your final reminder, MPN community 💙 The 2026 MPN Patient Unmet Needs Assessment closes March 18, and your voice...
03/09/2026

This is your final reminder, MPN community 💙

The 2026 MPN Patient Unmet Needs Assessment closes March 18, and your voice matters.

Whether this is your first time — or you participated in 2024 — your experience helps guide future research, education, and advocacy for myeloproliferative neoplasm (MPN) patients around the world.

🕒 Takes about 25 minutes

👉 Complete the assessment now: https://f.mtr.cool/itdfounaxz

Please consider sharing with other MPN patients so every voice is heard.

Nurse knowledge is power. Sharing it is impact.  As a nurse who cares for patients living with myeloproliferative neopla...
03/07/2026

Nurse knowledge is power. Sharing it is impact.

As a nurse who cares for patients living with myeloproliferative neoplasms (MPNs) and navigating the possibilities of disease progression, your role is critical.

Not only in delivering care, but in guiding patients through decisions that affect their long-term health and well-being. Your expertise and empathy help your MPN patients feel in control — even when questions and worries about disease progression make things feel uncertain.

Help share an opportunity with your eligible patients that empowers them and lets them contribute directly to future MPN research: the MPN PROGRESSion Registry™. Anyone 18 or older, living in the U.S., who has ever been diagnosed with an MPN can enroll.

👉 Learn more. Link in comments.

The 2026 MPN Patient Unmet Needs Assessment is now open — and your experience helps guide future research, education, an...
03/03/2026

The 2026 MPN Patient Unmet Needs Assessment is now open — and your experience helps guide future research, education, and advocacy for patients around the world.

If you participated in 2024, your input again is especially valuable. If not, we’d love to hear from you.

🕒 About 25 minutes
📅 Open until March 18, 2026

👉 Take the assessment today: https://f.mtr.cool/rcyyhkwvxr

Please share with other myeloproliferative neoplasm (MPN) patients, especially those outside the U.S., so every voice is heard.💙

Today is Rare Disease Day! Thanks to our incredible community, we’ve raised over $77,000 to advance MPN research. Your g...
03/01/2026

Today is Rare Disease Day! Thanks to our incredible community, we’ve raised over $77,000 to advance MPN research.

Your generosity helps us continue our over 25-year legacy of fueling scientific progress, supporting early discoveries, and bringing new treatments from bench to bedside.

If you haven’t joined in yet, it’s not too late! Every gift matters.

👉 Donate here: https://f.mtr.cool/rwbhfqilhf

Thank you for standing with the MPN community today.

You’re a myeloproliferative neoplasm (MPN) patient living in the U.S. and have been thinking about enrolling in the MPN ...
02/27/2026

You’re a myeloproliferative neoplasm (MPN) patient living in the U.S. and have been thinking about enrolling in the MPN PROGRESSion Registry™. But you want to know: Can it be trusted? Will my data be safe?

The MPN PROGRESSion Registry™ is committed to protecting your privacy and ensuring your data is secure in many ways.🔒

Swipe to learn more.

Address

PO Box 10743
Chicago, IL
60610

Alerts

Be the first to know and let us send you an email when MPN Research Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MPN Research Foundation:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram